Tailor Bio

Tailor Bio is a pan-cancer precision medicine company that focuses on developing an AI-driven drug discovery platform centered on Chromosomal Instability (CIN) biomarkers. Incorporated in September 2019 in the United Kingdom, the company aims to make precision medicine a practical reality for improving patients' lives. The core technology of Tailor Bio revolves around identifying CIN signatures, which are patterns of DNA copy number changes that indicate genetic instability in cancer samples. This approach allows for two main applications: drug target discovery, which involves identifying therapeutic targets based on CIN patterns, and patient stratification, which enhances the identification of patients suitable for targeted therapies by measuring CIN signature activity in their tumors. By understanding the causes of CIN in individual tumors, Tailor Bio supports informed therapy selection tailored to each patient's unique genetic profile.